Surprising findings show a low-salt diet doesn’t prevent death or hospital visits, but does improve symptoms and quality of life.
By UNIVERSITY OF ALBERTA
.webp)
Study reveals how reducing sodium intake can help patients with
heart failure.
For the past century people with weak hearts have been told to lower their salt intake, but until now there has been little scientific evidence behind the recommendation.
The largest randomized clinical trial to look at sodium reduction
and heart failure reported results simultaneously in The Lancet and at the American College of
Cardiology’s 71st Annual Scientific Session
over the weekend, and the findings were mixed.
Though reducing salt intake did not lead to fewer emergency
visits, hospitalizations or deaths for patients with heart failure, the
researchers did find an improvement in symptoms such as swelling, fatigue, and
coughing, as well as better overall quality of life.
“We can no longer put a blanket recommendation across all patients and say that limiting sodium intake is going to reduce your chances of either dying or being in the hospital, but I can say comfortably that it could improve people’s quality of life overall,” said lead author Justin Ezekowitz, professor in the University of Alberta’s Faculty of Medicine & Dentistry and co-director of the Canadian VIGOUR Centre.
The researchers followed 806 patients at 26 medical centers in
Canada, the United States, Columbia, Chile, Mexico, and New Zealand. All were
suffering from heart failure, a condition in which the heart becomes too weak
to pump blood effectively. Half of the study participants were randomly
assigned to receive usual care, while the rest received nutritional counseling
on how to reduce their dietary salt intake.
Patients in the nutritional counseling arm of the trial were
given dietitian-designed menu
suggestions using foods from their own region and were
encouraged to cook at home without adding salt and to avoid high-salt
ingredients. Most dietary sodium is hidden in processed foods or restaurant
meals rather than being shaken at the table, Ezekowitz noted.
“The broad rule that I’ve learned from dietitians is that anything
in a bag, a box, or a can generally has more salt in it than you would think,”
said Ezekowitz, who is also a cardiologist at the Mazankowski Alberta Heart
Institute and director of the U of A’s Cardiovascular Research Institute,
The target sodium intake was 1,500 milligrams per day — or the
equivalent of about two-thirds of a teaspoon of salt — which is the Health Canada recommended
limit for most Canadians whether they have heart failure or not.
Before the study, patients consumed an average of 2,217 mg per
day, or just under one teaspoon. After one year of study, the usual care group
consumed an average of 2,072 mg of sodium daily, while those who received
nutritional guidance consumed 1,658 mg per day, a reduction of a bit less than
a quarter teaspoon equivalent.
The researchers compared rates of death from any cause,
cardiovascular hospitalization and cardiovascular emergency department visits
in the two study groups but found no statistically significant difference.
They did find consistent improvements for the low-sodium group
using three different quality of life assessment tools, as well as the New York Heart
Association heart failure classification, a measure of heart
failure severity.
Ezekowitz said that he will continue to advise heart failure
patients to cut back on salt, but now he will be clearer about the expected
benefits. He urges clinicians to recognize that dietary changes can be a useful
intervention for some of their patients.
The team will do further research to isolate a marker in the blood
of patients who benefited most from the low-sodium diet, with the aim of being
able to give more targeted individual diet prescriptions in the future. The
researchers will also follow up the trial patients at 24 months and five years
to determine whether further benefits are achieved over the long term.
Reference: “Reduction of dietary sodium to less than 100 mmol in
heart failure (SODIUM-HF): an international, open-label, randomised, controlled
trial” 2 April 2022, The Lancet.
DOI:
10.1016/S0140-6736(22)00369-5
Funding: Canadian Institutes of Health Research, University Hospital Foundation, Health Research Council of New Zealand